AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 191 min read$IAM

Rachlin Evan Lockwood purchased $11.5M of IAM (indirect holdings)

Rachlin Evan Lockwood purchased 718,750 indirectly-held shares of Iambic Therapeutics, Inc. (IAM) at $16.00 ($11.50M total) on 2026-10-16.

Original reporting
SEC EDGAR · Rachlin Evan Lockwood
Published Oct 19, 2026, 11:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 11:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IAM
Bullish
high confidence
Mentioned
$IAM
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IAMBullishLow
01

Why it matters

The disclosed purchase adds new material information about insider confidence, which may influence short‑term trading decisions.

02

Market read

Insider buying of $11.5M provides fresh material for traders assessing Iambic Therapeutics' stock momentum.

03

What to watch

Potential upcoming dilution from future financing rounds may offset insider buying impact.

Relevance 8/10Novelty 6/10Timing: after-market filing on 2026-10-16

Background

Form 4 filings disclose insider trades; a director's purchase is often viewed as a positive sign.

Company-level read

Ticker impact

$IAMBullishHigh confidence
Context

Director Rachlin Evan Lockwood bought 718,750 shares at $16 each, increasing his stake to 2.59 million shares.

Expected impact

modest upward pressure as investors price in insider confidence

Evidence & confidence

Form 4 is a primary source; the $11.5M purchase is sizable for a micro‑cap, indicating material insider interest.

Market effects

Sector

Limited; reflects confidence in Iambic Therapeutics' pipeline but does not affect broader biotech sector.

Regional

None; company is US‑listed with no immediate regional ripple.

Global

Low; insider transaction is company‑specific.

Counterpoint

What could challenge this read

The purchase could be a routine portfolio rebalancing rather than a bullish signal.

Key entities

  • Company
    Iambic Therapeutics, Inc.

    Biopharmaceutical company developing RNA‑based therapeutics.

  • Person
    Rachlin Evan Lockwood

    Director of Iambic Therapeutics who executed the purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IAM insider trading history →

Related articles

OCT 18
$UNHMed

Notable healthcare headlines for the week: J&J, UnitedHealth, and CVS in focus

UnitedHealth (UNH) raised 2026 earnings guidance after Q3 results beat estimates, with adjusted EPS at $4.69. Johnson & Johnson (JNJ) also raised full-year guidance. Roche (RHHBY) signed a $1.16B deal for an obesity drug. STERIS (STE) to acquire Xodus Medical for $2.1B. Iambic Therapeutics (IAM) debuted with a 10% rise. CVS (CVS) agreed to pay $315M over opioid prescription allegations.

tradingview.com3 min
OCT 16
$IAMHighAI 9/10

Iambic Therapeutics IPO Raises $150M, Stock Jumps

Iambic Therapeutics (IAM) raised $150M in its IPO, priced at $16, and saw shares jump 18% to close at $18.91. The company, which uses AI for drug discovery, has partnerships with AbbVie, Takeda, and Nvidia. It reported $12.8M revenue and a $50.1M net loss for H1 2026. Proceeds will fund oncology programs.

briefs.co2 min
OCT 15
$IAMMed

Nvidia-backed drug discovery firm Iambic climbs on trading debut

Iambic Therapeutics (IAM), backed by Nvidia (NVDA) and AbbVie (ABBV), rose 11% on its trading debut, reaching $17.95. The AI-driven drug discovery firm raised $150M via IPO, with net proceeds of $135M to advance its lead asset, IAM1363, in clinical trials. Investors include ARK Investment Management and Duquesne Family Office LLC.

tradingview.com4 min
OCT 15
$IAMHighAI 9/10

Nvidia-Backed AI Biotech Iambic Up 16% After $150 Million IPO

Iambic Therapeutics Inc., an AI-driven biotech firm backed by Nvidia, saw its shares rise 16% in its IPO debut, trading at $18.50 after raising $150 million. The company, which focuses on cancer drug discovery, now has a market value of $877 million. Proceeds will advance three early-stage drug candidates. Key investors include ARK Investment Management and Stanley Druckenmiller's Duquesne Family Office.

finance.yahoo.com6 min
OCT 15
$IAMHighAI 8/10

Iambic Therapeutics sets $16 IPO price, targets $150 million raise

Iambic Therapeutics priced its IPO at $16 per share, aiming to raise $150 million. The company will trade on Nasdaq under the ticker IAM. Proceeds will fund cancer drug development. Nvidia is a shareholder. Iambic reported $12.8M revenue and a $50.1M net loss for H1 2026, per Bloomberg.

qz.com2 min